Laura Huppert, MD, BA: Clinical Trials

1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	3	Active not recruiting 1, Completed 1, Recruiting 1

Follow Laura Huppert, MD, BA: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer ARX788, Computed Tomography (CT), Biospecimen Collection - HER2 Low Breast Carcinoma, Triple Negative Breast Cancer	Phase 2	Recruiting	Laura Huppert, MD, BA	36	2026-06-05	2026-06-11
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer	Phase 2	Active not recruiting	Laura Huppert, MD, BA	145	2019-07-08	2026-04-17
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Pembrolizumab, Carboplatin, Trastuzumab - Breast Cancer, Chest Wall Disease	Phase 2	Completed	Laura Huppert, MD, BA	76	2017-09-02	2025-12-22

Conditions studied

Breast Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)

Interventions

ARX788 (1)  ·  Amiloride (1)  ·  Carboplatin (1)  ·  Specimen Handling (1)  ·  Trastuzumab (1)  ·  avelumab (1)  ·  binimetinib (1)  ·  liposomal doxorubicin (1)  ·  pembrolizumab (1)  ·  sacituzumab govitecan (1)  ·  utomilumab (1)

Countries

United States (3)

Top investigators

Laura Huppert, MD (2)  ·  Neelima Vidula, MD (1)